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Vascular dysfunction, in particular microvascular pathology perhaps most closely associated with arterioles, is a cardinal sign in the development ofsystemic sclerosis (scleroderma). Altered vascular reactivity and structure provide only one element in a spectrum of pathological alterations associated with the clinical development of the disease. Nonetheless, the almost invariable pre-existence of Raynaud's phenomenon before the development of scleroderma makes it clear that altered blood vessel responsiveness is an early event in the progression of the disease. These considerations led Campbell and LeRoy to propose as early as 1975 that the primary cause of scleroderma involved endothelial cell damage and dysfunction. ' Since then, mainly as a consequence of the ability to isolate and culture endothelial cells routinely (first described in 1973), our understanding of endothelial cell biology has advanced rapidly.2 Previously thought of by many as at best a selective permeability barrier between blood and tissues, it is now apparent that endothelium regulates actively many aspects of vascular homeostasis. It can be regarded realistically as a cell type that responds to molecular signals generated locally or distantly and hence controls metabolic and cellular events in the tissues of the body, in a manner which is at least as all-pervading as neuronal regulation.
It still remains hypothetical that disturbance of endothelial cell function is a necessary or primary event for the development of scleroderma, but there is increasing evidence that the involvement of endothelial cells is an important element in the pathogenesis of the disease. This review outlines first our current understanding of several major aspects of endothelial cell biology, derangements of which might be expected to contribute to vascular pathology. In 16 Endothelial nitric oxide synthesis may therefore have a physiological role in the local control of blood flow, its release perhaps being regulated by shear sensitive or stretch sensitive receptors on the endothelium.'7-'9
More provocatively, Griffith and Edwards have argued that production of endothelium derived relaxing factor plays a necessary part in the efficient development and maintenance of the in vivo anatomy of microvascular beds.20
In the past three years it has been shown that endothelial cells also synthesise and secrete a highly potent vasoconstrictor peptide, endothelin. ' 27 Increased permeability also occurs.when neutrophil binding to endothelium is induced by alterations in endothelial surface leucocyte adhesion molecules, or when intravascular or perivascular neutrophil activation leads to overt damage to endothelium28 (and see below).
CONTROL OF HAEMOSTASIS AND THROMBOSIS
Endothelium is normally antithrombotic and anticoagulant. This is due in part to mechanisms at the cell surface, including the expression of heparin-like proteoglycans and of thrombomodulin, which avidly binds thrombin and renders it anticoagulant by altering its proteolytic specificity so that it activates protein C (which in turn inactivates coagulation factors V and VIII) rather than cleaving fibrinogen. 29 In addition, local control of fibrinolysis is due to the triggered secretion of tissue plasminogen activator from endothelium in response to several agonists, such as thrombin or vasopressin.30 Endothelium also produces the circulating physiological inhibitor of tissue plasminogen activator, though the details of how its secretion is regulated are not well understood. 31 The highly multimerised glycoprotein von Willebrand factor, which in the circulation acts as a carrier for coagulation factor VIII, is constitutively secreted by endothelial cells. In addition, von Willebrand factor is a cofactor for platelet adhesion to subendothelium, and its release from granular stores in endothelial cells is triggered by exposure to agonists similar to those that induce secretion of tissue plasminogen activator.32 Thus thrombin, for example, which initially stimulates platelet aggregation and coagulation to produce a haemostatic plug at a site of vessel damage, also induces endothelial cell responses designed to localise and limit thrombus formation.
A further way in which this is achieved is due to the receptor mediated stimulation of prostacyclin release from endothelial cells in response to agonists, including thrombin, and ATP and ADP released from aggregating platelets. 33 Prostacyclin is a potent inhibitor of platelet aggregation, and in several vascular beds is also a potent dilator. Because it is released transiently in response to a range of agonists, of which many also induce release of endothelium derived relaxing factor, prostacycin can also contribute to endothelium dependent vaso 43 In general, however, they require protein synthesis and are expressed, after a lag period, for several hours in distinct but overlapping patterns in response to different cyto-kines. Thus treatment of endothelium with interleukin 1, tumour necrosis factor a, or bacterial lipopolysaccharide induces greatly augmented neutrophil adhesion, which in vitro peaks at about four to six hours and has returned to near basal levels within 24 hours. This is due, at least in part, to the induction of endothelial-leucocyte adhesion molecule 1 on endothelium, which specifically binds to an as yet unidentified neutrophil surface ligand, though adhesion mechanisms independent of this adhesion molecule are also evident." 4 Enhancement of lymphocyte adhesion, which occurs over a longer time course (peak at 24 hours in vitro), is correlated with the increased expression of intercellular adhesion molecule 1 on endothelium, which forms a ligand pair with the leucocyte surface molecule lymphocyte function associated antigen 1L.' More recently, pretreatment with interleukin 4 (a T cell derived cytokine) was found to enhance lymphocyte adhesion to endothelium,47 and this may be related to the expression of another endothelial surface molecule, vascular cell adhesion molecule 1, known to be a lymphocyte adhesion receptor. 48 Interferon y uniquely increases the expression of Ia (major histocompatibility complex class II) molecules on endothelial cells, in addition to upregulating lymphocyte adhesion. 49 The potential role of endothelium as an antigenpresenting cell type has been confirmed in vitro, where interferon treated endothelial cells were shown to present antigen specifically to sensitised lymphocytes and to induce lymphocyte proliferation with a comparable efficiency to macrophages.50 Endothelial cells may do this by lymphokine (interferon y or interleukin 1) stimulation of endothelial interleukin 6 production,51 which in turn stimulates lymphocyte interleukin 2 production to drive proliferation. Smooth muscle cells also secrete interleukin 6, however, in response to lymphokines, and present Ia antigens, but are poor stimulators of lymphocyte proliferation. Recently, an endothelial cell-specific mechanism, requiring cell contact with lymphocytes to induce proliferation, was In the light of the likely importance of basal and agonist stimulated release of endothelium derived relaxing factor (nitric oxide) for the control of blood pressure and flow it is reasonable to speculate that a failure of this mechanism is involved in the microvascular pathology of scleroderma. Although I am not aware of studies that have considered directly whether endothelium dependent vasodilator responses are selectively impaired in patients with scleroderma, this hypothesis is consistent with the observations that diseased vessels relax to endothelium independent dilators. In addition, in the absence of endothelium derived relaxing factor production several endothelium dependent vasodilators-for example, serotonin, ATP, acetylcholine-cause direct vasoconstriction and have been implicated in the generation of vessel spasm in atherosclerosis.' Furthermore, the changes in capillary morphology in scleroderma might be a consequence of arteriolar dysfunction, leading to altered flow patterns.20 EVIDENCE 74 The likelihood that such events occur in vivo in scleroderma is enhanced by the evidence for increased interleukin 2 production in patients with scleroderma.75 76 Damage to endothelium by non-immune mechanisms has also been described. Kahaleh 
